Arthur J. Gallagher Free cash flow increased by 29.1% to $921.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $844.00M to $921.00M. Over 2 years (FY 2021 to FY 2024), Free cash flow shows an upward trend with a 39.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $438.20M | $477.40M | $156.70M | $178.90M | $592.50M | $565.50M | $398.80M | $0.00 | $838.40M | $647.50M | $759.60M | $87.70M | $898.00M | $695.70M | $844.00M | $693.50M | $713.40M | $921.00M |
| QoQ Change | — | +8.9% | -67.2% | +14.2% | +231.2% | -4.6% | -29.5% | -100.0% | — | -22.8% | +17.3% | -88.5% | +923.9% | -22.5% | +21.3% | -17.8% | +2.9% | +29.1% |
| YoY Change | — | — | — | — | +24.1% | +260.9% | +122.9% | — | +41.5% | +14.5% | +90.5% | — | +7.1% | +7.4% | +11.1% | -22.8% | +2.5% | +9.1% |